Allogeneic CD7KO Anti-CD7 Universal CAR-T Cells CTD402

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic, off-the-shelf (OTS), universal, gene-edited T-lymphocytes, in which the tumor-associated antigen (TAA) CD7 is knocked out (CD7KO) and human leukocyte antigen (HLA) class II expression is disrupted, and is genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD7, the co-stimulatory molecule 4-1BB (CD137) and the intracellular CD3 zeta domain (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CD7KO anti-CD7 universal CAR-T cells CTD402 specifically target and kill CD7-expressing tumor cells. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas. CD7 KO in the CAR-T cells prevents CAR-T fratricide and enhances CAR-T cell function. The downregulation of the expression of HLA protects the CAR-T cells from host immune rejection and graft-versus-host disease (GvHD).

**Synonyms:** - Allogeneic CD7KO Anti-CD7 CAR T Cells CTD402 - Allogeneic CD7KO Anti-CD7 CAR T-cells CTD402 - Allogeneic CD7KO Anti-CD7 UCAR-T Cells CTD402 - Allogeneic CD7KO Anti-CD7 UCART Cells CTD402 - CTD 402 - CTD-402 - CTD402